Endocyte Inc (ECYT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Endocyte Inc (ECYT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7978
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:52
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Endocyte Inc (Endocyte) is a biopharmaceutical company that develops targeted therapies for the treatment of cancer and inflammatory diseases. The company’s pipeline products include Lu-PSMA-617 and Ac-PSMA-617 for radiologand therapy, and FITC CAR-T. Endocyte’s proprietary small molecule drug conjugate (SMDC) technology is used to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company develops therapeutic immunotherapy approach that involves potent immune cells, called chimeric antigen receptor T-cell (CAR T-cell) to fight cancer. It has operations in Indianapolis and West Lafayette. Endocyte is headquartered in West Lafayette, Indiana, the US.

Endocyte Inc (ECYT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10
Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Endocyte Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Kyzeo Imaging Enters into Agreement with Endocyte 12
Endocyte Enters into Agreement Seattle Children’s Research Institute 13
Licensing Agreements 14
Endocyte Receives Rights from Radiomedix 14
Endocyte Enters into Licensing Agreement with ABX 15
Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide 16
Equity Offering 17
Endocyte Raises USD201.2 Million in Public Offering of Shares 17
Endocyte Raises USD86.3 Million in Public Offering of Shares 18
Endocyte Plans to Raise up to USD150 Million in Public Offering of Securities 19
Endocyte Raises Funds through Private Placement of Shares and Warrants 20
Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants 21
Endocyte Completes Public Offering Of Shares For US$108.7 Million 22
Acquisition 23
Novartis to Acquire Endocyte 23
Endocyte Inc – Key Competitors 25
Endocyte Inc – Key Employees 26
Endocyte Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Jul 31, 2018: Endocyte provides second quarter 2018 financial results and operational update 28
May 09, 2018: Endocyte Provides First Quarter 2018 Financial Results and Operational Update 30
Nov 06, 2017: Endocyte Reports Third Quarter Financial Results 32
Aug 08, 2017: Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update 34
May 10, 2017: Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update 36
Mar 10, 2017: Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update 38
Corporate Communications 40
Mar 15, 2018: Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments 40
Feb 27, 2018: Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors 41
Feb 21, 2017: Endocyte Appoints Michael T. Andriole as Chief Financial Officer 42
Product News 43
10/17/2017: New Potential Treatment for Prostate Cancer Receives Boost 43
09/06/2017: Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy 44
04/16/2018: Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018 45
Clinical Trials 46
Sep 05, 2017: Endocyte Announces Presentation at the European Society for Medical Oncology 46
Jun 02, 2017: Endocyte Announces Clinical Update for EC1169 47
May 26, 2017: Endocyte to Announce Updated Data on clinical-stage asset EC1169 at the 2017 American Society of Clinical Oncology Annual Meeting 48
Other Significant Developments 49
Oct 03, 2018: Endocyte becomes first Purdue startup to reach $1.5B in value 49
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52

List of Tables
Endocyte Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Endocyte Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10
Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kyzeo Imaging Enters into Agreement with Endocyte 12
Endocyte Enters into Agreement Seattle Children's Research Institute 13
Endocyte Receives Rights from Radiomedix 14
Endocyte Enters into Licensing Agreement with ABX 15
Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide 16
Endocyte Raises USD201.2 Million in Public Offering of Shares 17
Endocyte Raises USD86.3 Million in Public Offering of Shares 18
Endocyte Plans to Raise up to USD150 Million in Public Offering of Securities 19
Endocyte Raises Funds through Private Placement of Shares and Warrants 20
Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants 21
Endocyte Completes Public Offering Of Shares For US$108.7 Million 22
Novartis to Acquire Endocyte 23
Endocyte Inc, Key Competitors 25
Endocyte Inc, Key Employees 26
Endocyte Inc, Other Locations 27

List of Figures
Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Endocyte Inc (ECYT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Camel-IDS NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Camel-IDS NV (Camel-IDS) is a biotechnology company that develops radio-immunotherapeutic drugs for cancer patients. The company offers developing of compound radiopharmaceutical drugs for treatment of Her2 positive cancer. Its technology platform is based on recombinant, small antigen-bindi …
  • Jaya Tiasa Holdings Berhad (JTIASA):企業の財務・戦略的SWOT分析
    Jaya Tiasa Holdings Berhad (JTIASA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • The Bank of Kochi, Ltd.:企業の戦略・SWOT・財務情報
    The Bank of Kochi, Ltd. - Strategy, SWOT and Corporate Finance Report Summary The Bank of Kochi, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Power Grid Corporation of India Ltd (POWERGRID EQ):企業の財務・戦略的SWOT分析
    Power Grid Corporation of India Ltd (POWERGRID EQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Salzgitter Klockner-Werke GmbH:企業の戦略・SWOT・財務情報
    Salzgitter Klockner-Werke GmbH - Strategy, SWOT and Corporate Finance Report Summary Salzgitter Klockner-Werke GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • SymBio Pharmaceuticals Ltd (4582):企業の財務・戦略的SWOT分析
    Summary SymBio Pharmaceuticals Ltd (SymBio) is a biopharmaceutical company that develops and markets anti-cancer drug candidates. Its pipeline product portfolio includes Treakisym (SyB L-0501), an anti-cancer agent used for the treatment of non-Hodgkin's lymphoma (NHL), multiple myeloma (MM) and chr …
  • KPMG International:企業の戦略・SWOT・財務情報
    KPMG International - Strategy, SWOT and Corporate Finance Report Summary KPMG International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Advanced Proteome Therapeutics Corp (APC):企業の財務・戦略的SWOT分析
    Advanced Proteome Therapeutics Corp (APC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • CLP Holdings Ltd:企業の発電所・SWOT分析2018
    CLP Holdings Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (e …
  • Bawag Psk
    Bawag Psk - Strategy, SWOT and Corporate Finance Report Summary Bawag Psk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Centrus Energy Corp.:企業の戦略・SWOT・財務分析
    Centrus Energy Corp. - Strategy, SWOT and Corporate Finance Report Summary Centrus Energy Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Sinclair Broadcast Group, Inc.:企業の戦略・SWOT・財務分析
    Sinclair Broadcast Group, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sinclair Broadcast Group, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Echelon Corporation (ELON):企業の財務・戦略的SWOT分析
    Echelon Corporation (ELON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • LT Group, Inc. (LTG):企業の財務・戦略的SWOT分析
    LT Group, Inc. (LTG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • AGF Management Ltd:企業の戦略・SWOT・財務分析
    AGF Management Ltd - Strategy, SWOT and Corporate Finance Report Summary AGF Management Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Guardant Health Inc (GH):医療機器:M&Aディール及び事業提携情報
    Summary Guardant Health Inc (Guardant Health) is a non-invasive cancer diagnostics company that commercializes genomic liquid biopsy. The company develops proprietary digital sequencing technology used to detect individual genomic alterations. It offers Guardant360, a tool for early cancer detection …
  • Tyser & Co Limited:企業の戦略的SWOT分析
    Tyser & Co Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Grifols SA (GRF):企業の財務・戦略的SWOT分析
    Grifols SA (GRF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • IDG Communications Inc:企業の戦略的SWOT分析
    IDG Communications Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • UBM plc:企業のM&A・事業提携・投資動向
    UBM plc - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's UBM plc Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital ra …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆